Hodgkin's lymphoma Cancer Hodgkin's lymphoma
Conditions
Interventions
The patient either receives the VEPEMB treatment or is simply registered on the database and the alternative treatment which they receive is recorded. The patient's treatment is determined by their ph
Sponsors
Newcastle Hospitals NHS Trust (UK)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Histologically confirmed classical Hodgkin's Lymphoma (HL) 2. No previous treatment for HL 3. Aged over 60 4. "Non fragile" patients, i.e. patient?s mental and physical status must be sufficient to withstand the treatment described 5. No concomitant neoplasia or known Human Immunodeficiency Virus (HIV) infection 6. Written informed consent
Exclusion criteria
Exclusion criteria: 1. Nodular Lymphocyte Predominance Hodgkin's Lymphoma (NLPHL) 2. Aged under 60 3. Patient previously treated for HL 4. Known HIV infection or concomitant neoplasia 5. "Fragile patient" or significant abnormality of another system (pulmonary, cardiac, renal, and hepatic) which is a contraindication to full dose chemotherapy 6. Unable to give informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary endpoints will be progression-free survival, with clinical progression and death as the events. On suspicion of progression (e.g. new or enlarging masses, development of ?B? symptoms) patients should be re-evaluated according to normal procedures to confirm relapse. Histological confirmation of relapse is recommended but not mandatory. Survival time, including death from any cause, will also be investigated. For both endpoints, the event-free times will be dated from the date of histological diagnosis. | — |
Secondary
| Measure | Time frame |
|---|---|
| Analysis will be done to assess potential prognostic factors (Epstein-Barr Virus [EBV] status, "Fragility" assessment, Hasenclever index, soluble form of the CD30 molecule [sCD30]) which might be relevant in this age group. | — |
Countries
United Kingdom
Outcome results
None listed